CJC-1295 no DAC 5mg (Mod GRF 1-29)

Name: CJC-1295 no DAC 5mg (Mod GRF 1-29)
SKU: 28
Availability: InStock

$49.50

CJC-1295 (no DAC) (Modified GRF) is a research peptide, also known as Mod GRF (1–29), a tetrasubstituted analog of growth hormone–releasing hormone (GHRH 1–29) engineered for enhanced stability and receptor affinity without Drug Affinity Complex (DAC) conjugation. It activates the GHRH receptor to stimulate adenylate cyclase and cAMP signaling, leading to activation of somatotropic signaling pathways under experimental conditions. Mod GRF (1–29) is used in research focused on peptide pharmacokinetics and pituitary receptor regulation mechanisms.

For research use only. Not for human consumption.

References:
Frohman LA et al., Endocr Rev, 2001;22(6):606–648
Ip E et al., Endocrinology, 2005;146(7):3060–3066
Momany FA et al., Endocrinology, 1981;108(1):31–39

SKU: 28 Category: All Peptides Tags: nbsp, peptide, receptor, research, signaling

Description

CJC-1295 no DAC 5mg (Mod GRF 1-29) – Buy High-Quality CJC-1295 no DAC 5mg (Mod GRF 1-29) Online

Looking to buy CJC-1295 no DAC 5mg (Mod GRF 1-29) for your research laboratory? You have come to the right place. We currently have CJC-1295 no DAC 5mg (Mod GRF 1-29) for sale and it is in stock and ready for immediate shipping. Our CJC-1295 no DAC 5mg (Mod GRF 1-29) is of the highest purity, making it the best CJC-1295 no DAC 5mg (Mod GRF 1-29) online for scientific studies.

Product Overview

CJC-1295 no DAC 5mg (Mod GRF 1-29) is a premium research compound widely utilized in various scientific studies. Researchers seeking to buy CJC-1295 no DAC 5mg (Mod GRF 1-29) online often prioritize purity and consistency. This compound has been studied extensively for its unique biochemical properties and its role in cellular pathways.

Overview

Modified GRF (1-29) is a synthetic peptide corresponding to the N-terminal 29–amino acid region of growth hormone–releasing factor (GRF), incorporating targeted amino acid substitutions to increase biochemical stability in experimental systems. This truncated analogue represents the GRF domain commonly used in laboratory studies focused on endocrine signaling and peptide–receptor interaction workflows.

The compound is commonly referenced in the scientific literature as CJC-1295 without DAC, distinguishing it from affinity-modified, extended-duration variants. In research settings, this non-DAC format is used to investigate receptor engagement, early signal initiation, and temporal pathway dynamics under controlled preclinical conditions.

This material is supplied strictly for research use in in-vitro experiments and in-vivo animal model studies.

Biochemical Characteristics

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molar Mass: 3368.7 g/mol
Synonyms: Mod GRF 1-29, CJC-1295 (no DAC)

Modified GRF (1-29) molecular structure

The substitution of D-alanine at position 2 is used in experimental peptide design to reduce susceptibility to enzymatic cleavage observed for native sequence motifs in biological matrices. C-terminal amidation is included to support conformational stability and consistent receptor-interaction behavior during in-vitro analysis.

Research Applications

Modified GRF (1-29) is used in laboratory research to investigate growth hormone–releasing hormone receptor (GHRHR) activation and associated intracellular signaling cascades. The peptide is applied as a tool compound for studying ligand–receptor dynamics, receptor kinetics, and second-messenger pathway modulation in controlled experimental systems.

Common experimental applications include:

GHRHR binding affinity and kinetics assays
Adenylate cyclase activation and cyclic AMP signaling studies
Structure–activity relationship (SAR) comparisons among GRF(1-29) analogues
Endocrine and neuroendocrine signaling investigations in cellular and animal research models

The absence of DAC modification is leveraged in experimental design to evaluate transient signaling events without long-acting affinity contributions.

Pathway / Mechanistic Context

Modified GRF (1-29) interacts with the growth hormone–releasing hormone receptor (GHRHR), a class B G protein–coupled receptor frequently studied for its primary coupling to G_s signaling. In canonical models, receptor activation stimulates adenylate cyclase activity, increasing intracellular cyclic AMP and engaging PKA-linked phosphorylation events and downstream transcriptional regulators.

This signaling axis is used in preclinical research to characterize receptor specificity, signal amplification, temporal activation patterns, and feedback regulation mechanisms within endocrine and neuroendocrine model systems.

Preclinical Research Summary

Preclinical studies employing Modified GRF (1-29) have focused on receptor activation profiles, comparative potency among GRF analogues, and intracellular signaling kinetics in cell-based systems. In vivo animal studies have been used to examine endocrine-axis signaling regulation and peptide distribution characteristics using established laboratory endpoints.

These investigations contribute to foundational knowledge regarding peptide hormone signaling mechanisms and receptor pharmacology. All reported findings are derived exclusively from non-clinical experimental systems.

Form & Analytical Testing

This peptide is supplied as a lyophilized solid intended to support stability during storage and transport prior to laboratory handling. Product identity and purity are verified using established analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS).

All materials are manufactured under controlled laboratory conditions to support batch-to-batch consistency for research reproducibility.

Referenced Citations

L. Jetté et al., “Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog,” Endocrinology, vol. 146, no. 7, pp. 3052–3058, 2005. [PubMed]
L. A. Frohman et al., “Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH₂ terminus,” J. Clin. Invest., vol. 78, no. 4, pp. 906–913, 1986. [PubMed] [PMC]
J. Izdebski et al., “New potent hGH-RH analogues with increased resistance to enzymatic degradation,” J. Pept. Sci., vol. 8, no. 7, pp. 289–296, 2002. [PubMed]

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

RUO Disclaimer

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.

Storage Instructions:

All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.

Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you’re ready to reconstitute it with bacteriostatic water.

Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4C (39F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.

However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80C (-112F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability.

Why Choose Our CJC-1295 no DAC 5mg (Mod GRF 1-29)?

When you are looking for CJC-1295 no DAC 5mg (Mod GRF 1-29) for sale, quality is paramount. Our products undergo rigorous testing to ensure they meet the strict requirements of laboratory environments. By choosing to buy CJC-1295 no DAC 5mg (Mod GRF 1-29) from our store, you are guaranteed a product that is:

High Purity (Tested for 99% )
Fast Shipping – Always in stock
Secure Packaging for Research Integrity
Competitive Pricing for Bulk Orders

Specifications & Technical Data

Feature	Specification
Product Name	CJC-1295 no DAC 5mg (Mod GRF 1-29)
SKU	28
Purity	>99%
Form	Research Grade Compound
Availability	In Stock / For Sale

Scientific Research & Clinical Applications

The research surrounding CJC-1295 no DAC 5mg (Mod GRF 1-29) is vast. Scientists explore its potential in various metabolic and physiological models. For more detailed scientific data, you can visit PubMed to review the latest peer-reviewed literature regarding this compound.

Frequently Asked Questions

Where can I buy CJC-1295 no DAC 5mg (Mod GRF 1-29)?

You can buy CJC-1295 no DAC 5mg (Mod GRF 1-29) directly from our website. We provide a secure checkout and fast shipping to ensure your research stays on track.

Is CJC-1295 no DAC 5mg (Mod GRF 1-29) in stock?

Yes, we currently have CJC-1295 no DAC 5mg (Mod GRF 1-29) in stock. Orders are typically processed within 24 hours to ensure rapid delivery to your laboratory.